Savara Inc. (SVRA) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. Savara Inc. is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. Its sole program is MOLBREEVI, an investigational inhaled biologic (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). The company has no product revenue to date and operates as a single segment.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(29.6) million | $(24.2) million | $(86.6) million | $(66.8) million |
| Net Loss Per Share | $(0.14) | $(0.11) | $(0.40) | $(0.35) |
| Operating Expenses | $30.3 million | $26.4 million | $90.1 million | $72.0 million |
| Cash & Cash Equivalents | As of Sept 30, 2025: Cash: $16.3 million Short-term Investments: $108.1 million Total Liquidity: $124.4 million |
|||
| Long-Term Debt | ||||
| Accumulated Deficit | As of Sept 30, 2025: $(575.9) million |
Material Changes vs. Prior Period
- Expense Growth: Total operating expenses increased by $3.9 million (14.8%) in Q3 2025 compared to Q3 2024. General and Administrative (G&A) expenses rose significantly by $3.6 million (60.1%), driven by strategic personnel additions and commercial preparation. Research and Development (R&D) expenses increased slightly by $0.3 million.
- Debt Restructuring: In March 2025, the company entered a new $200 million credit facility with Hercules Capital, drawing an initial $30 million tranche to repay its prior Silicon Valley Bank loan. This resulted in a $0.5 million loss on extinguishment of debt recorded in the YTD 2025 period.
- Investment Portfolio: Short-term investments decreased from $181.2 million at year-end 2024 to $108.1 million at Q3 2025, reflecting maturities and purchases to manage liquidity.
- Regulatory Status: In May 2025, the FDA issued a Refusal to File (RTF) letter for the MOLBREEVI Biologics License Application (BLA). The company plans to resubmit the BLA in December 2025.
Guidance, Outlook, and Risks
- Capital Raise (Subsequent Event): On October 31, 2025, Savara completed an underwritten public offering raising approximately $140.0 million in net proceeds. This significantly extends the company's cash runway.
- Royalty Sale (Subsequent Event): On October 29, 2025, the company entered an agreement to sell U.S. royalty rights for MOLBREEVI to RTW Investments for a potential $75.0 million, contingent on FDA approval by March 31, 2027.
- Government Shutdown Risk: A U.S. federal government shutdown effective October 1, 2025, has impacted FDA operations. While critical functions continue, the company notes potential delays in the acceptance or review of its BLA resubmission.
- Litigation: A putative securities class action lawsuit was filed on September 8, 2025, alleging violations related to public statements regarding regulatory filings. The company intends to vigorously defend the claims.
- Outlook: Management expects to continue incurring significant operating losses as it advances clinical development and prepares for commercialization. The company believes current liquidity (including the October 2025 proceeds) is sufficient to fund operations for at least the next 12 months.
Investor Verification Checklist
- BLA Resubmission Timeline: Verify the status of the December 2025 BLA resubmission and any potential delays caused by the ongoing government shutdown.
- Debt Covenants: Review the specific "Cash Requirement" and "Conditional Minimum Revenue Covenant" in the Hercules Loan Agreement, which may require maintaining 50-70% of outstanding principal in cash or achieving specific revenue milestones.
- Royalty Sale Conditions: Confirm the specific closing conditions for the $75 million royalty sale, particularly the requirement for FDA approval by March 31, 2027.
- Litigation Exposure: Monitor the progress of the securities class action filed in September 2025 for potential settlement costs or diversion of management resources.
- Manufacturing Commitments: Assess the $31.6 million in estimated fees for FujiFilm Diosynth and other manufacturing obligations to ensure alignment with cash flow projections.